Recent Press Releases

Expert Briefing on Health Care Sector Stocks - Edwards Lifesciences, Catamaran, Quest Diagnostics, Aetna, and WellPoint

Editor Note: For more information about this release, please scroll to bottom.

LONDON, September 15, 2014

Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis

Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting

THOUSAND OAKS, Calif.,

Actor James Van Der Beek and AstraZeneca Join Forces to Educate Families about Influenza

The makers of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) and the "CSI: Cyber" star launch national campaign to dispel common misconceptions about flu and annual vaccination

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density

Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016

THOUSAND OAKS, Calif. and

Cheaper alternative to licensed drug for treating eye disease has similar side effects, says new Cochrane Review

Cheaper alternative to licensed drug for treating eye disease has similar side effects, says new Cochrane Review Health policies which favour using ranibizumab for treating eye disease in older...

Lupin and Salix Announce Exclusive Distribution Agreement for Canada

Lupin and Salix Announce Exclusive Distribution Agreement for Canada Zaxine®, Relistor® and Other Gastroenterology Products September 12, 2014 Lupin Limited (Lupin) and Salix...

Cipla enters into a licensing agreement with Gilead to increase access to Hepatitis C treatment

India, Mumbai, 15th September 2014: Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients today announced that...

Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries

PITTSBURGH and HYDERABAD, India, Sept. 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead...

Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries

-- Indian companies granted license to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C -- NEW DELHI--(BUSINESS...

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time

<

Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure

Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Gro

Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen --

IND

New data confirm high efficacy of Gilenya(R) in achieving 'no evidence of disease activity (NEDA)' based on four key measures of MS

(Thomson Reuters ONE via COMTEX) -- Novartis International AG / New data confirm high efficacy of Gilenya(R) in achieving 'no evidence of disease activity (NEDA)' based on four key measures...

Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and...

Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal

Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/12/14 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical...

Cyclacel Pharmaceuticals, Inc. (CYCC) Appoints Samuel L. Barker, Ph.D. To Board Of Directors

Cyclacel Pharmaceuticals, Inc. (CYCC) Appoints Samuel L. Barker, Ph.D. To Board Of Directors BERKELEY HEIGHTS, N.J., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC)...

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company Separation into two publicly traded companies remains on track for mid-2015 September 10, 2014 04:30 PM Eastern Daylight...

U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer

Approval Based on Improved Overall Survival, Delayed Time to Radiographic Progression and an Overall Positive Benefit-Risk Profile SAN FRANCISCO, CA and TOKYO, JAPAN -- (Marketwired) -- 09/10/14...

Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management

Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management New Medication for Obese Adults, or Overweight...

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies In approximately 70 percent of patients, disability scores improved...